📊 MIRA Key Takeaways
Is MIRA a Good Investment? Thesis Analysis
Mira Pharmaceuticals is a pre-revenue pharmaceutical company with severe cash burn and deteriorating financial performance. The company generated only $98.9K in revenue (down 40% YoY) while operating losses widened, with net losses of $10.4M consuming cash at an unsustainable rate. At current burn rate, the company's $6.3M cash position provides less than 2 quarters of runway, creating critical going concern risk without immediate capital injection or dramatic operational changes.
Why Buy MIRA? Key Strengths
- Strong liquidity position with $6.3M cash and 15.75x current ratio
- Minimal debt burden with no long-term debt obligations
- Pharmaceutical sector offers high-value commercialization potential if pipeline succeeds
MIRA Investment Risks to Consider
- Severe revenue decline (-40% YoY) indicates failed market traction or product commercialization
- Net loss of $10.4M with only $98.9K revenue creates unsustainable -10,557% net margin
- Operating cash burn of $4.7M quarterly with limited runway; cash will deplete within 6 quarters at current rates
- No insider buying activity in 90 days suggests lack of management confidence
- Early-stage pharmaceutical companies with minimal revenue face existential risk of capital exhaustion
Key Metrics to Watch
- Quarterly revenue and revenue growth trajectory
- Monthly cash burn rate and months of runway remaining
- Operating loss trends and path to profitability timeline
- Pipeline advancement milestones and regulatory progress
- Capital raising announcements and dilution impact
MIRA Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 15.75x current ratio provides a solid financial cushion.
MIRA Profitability Ratios
MIRA vs Healthcare Sector
How MIRA PHARMACEUTICALS, INC. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is MIRA Overvalued or Undervalued?
Based on fundamental analysis, MIRA PHARMACEUTICALS, INC. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
MIRA Balance Sheet & Liquidity
MIRA 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: MIRA PHARMACEUTICALS, INC.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.51 indicates the company is currently unprofitable.
MIRA Growth Metrics (YoY)
MIRA Capital Allocation
MIRA SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for MIRA PHARMACEUTICALS, INC. (CIK: 0001904286)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MIRA
What is the AI rating for MIRA?
MIRA PHARMACEUTICALS, INC. (MIRA) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are MIRA's key strengths?
Claude: Strong liquidity position with $6.3M cash and 15.75x current ratio. Minimal debt burden with no long-term debt obligations.
What are the risks of investing in MIRA?
Claude: Severe revenue decline (-40% YoY) indicates failed market traction or product commercialization. Net loss of $10.4M with only $98.9K revenue creates unsustainable -10,557% net margin.
What is MIRA's revenue and growth?
MIRA PHARMACEUTICALS, INC. reported revenue of $98.9K.
Does MIRA pay dividends?
MIRA PHARMACEUTICALS, INC. does not currently pay dividends.
Where can I find MIRA SEC filings?
Official SEC filings for MIRA PHARMACEUTICALS, INC. (CIK: 0001904286) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MIRA's EPS?
MIRA PHARMACEUTICALS, INC. has a diluted EPS of $-1.35.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MIRA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, MIRA PHARMACEUTICALS, INC. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is MIRA stock overvalued or undervalued?
Valuation metrics for MIRA: ROE of -100.5% (sector avg: 15%), net margin of -10,557.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy MIRA stock in 2026?
Our dual AI analysis gives MIRA PHARMACEUTICALS, INC. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MIRA's free cash flow?
MIRA PHARMACEUTICALS, INC.'s operating cash flow is $-4.7M, with capital expenditures of N/A. FCF margin is -4,713.0%.
How does MIRA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -10,557.5% (avg: 12%), ROE -100.5% (avg: 15%), current ratio 15.75 (avg: 2).